Therwil, Switzerland

James Richard Martin


Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 30(Granted Patents)


Company Filing History:


Years Active: 2001-2002

Loading Chart...
2 patents (USPTO):Explore Patents

Title: **James Richard Martin: Pioneering Antiepileptic Innovations**

Introduction

James Richard Martin is an esteemed inventor based in Therwil, Switzerland, recognized for his significant contributions to the field of pharmaceuticals. With a total of two patents, Martin focuses on developing innovative methods aimed at enhancing therapeutic outcomes for psychiatric and neurological disorders.

Latest Patents

Among his latest patents, the invention of an Imidazodiazepine derivative stands out. This innovative method is dedicated to identifying compounds that possess antiepileptic, anticonvulsant, or anxiolytic activities. The current invention spans a method for screening therapeutically useful compounds by testing an LC132 receptor agonist in a specialized screening assay. This method involves contacting the LC132 receptor with an agent suspected of being an agonist, followed by detecting the compound’s binding and/or agonist activity. The innovative process culminates in testing agents with LC132 agonist activity through antiepileptic, anticonvulsant, or anxiolytic screening assays.

Career Highlights

James Richard Martin currently lends his expertise to Hoffmann-La Roche Inc., a prominent leader in the pharmaceutical industry. His work in the development of groundbreaking therapeutic methods underscores his commitment to advancing medical science and improving patient care.

Collaborations

Throughout his career, Martin has collaborated with notable colleagues, including Olivier Civelli and Frederick Monsma. These partnerships have been instrumental in driving forward innovative research and methodologies in their field.

Conclusion

James Richard Martin's dedication to inventing novel methods for treating psychiatric and neurological disorders showcases his invaluable contributions to the pharmaceutical sector. With a focus on LC132 receptor agonists and a commitment to improving therapeutic outcomes, Martin continues to be a driving force in innovation, paving the way for future advancements in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…